Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific - PubMed (original) (raw)
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific
A M Thornton et al. J Immunol. 2000.
Abstract
CD4+CD25+ T cells represent a unique population of "professional" suppressor T cells that prevent induction of organ-specific autoimmune disease. In vitro, CD4+CD25+ cells were anergic to simulation via the TCR and when cultured with CD4+CD25- cells, markedly suppressed polyclonal T cell proliferation by specifically inhibiting the production of IL-2. Suppression was cytokine independent, cell contact dependent, and required activation of the suppressors via their TCR. Further characterization of the CD4+CD25+ population demonstrated that they do not contain memory or activated T cells and that they act through an APC-independent mechanism. CD4+CD25+ T cells isolated from TCR transgenic (Tg) mice inhibited responses of CD4+CD25- Tg T cells to the same Ag, but also inhibited the Ag-specific responses of Tg cells specific for a distinct Ag. Suppression required that both peptide/MHC complexes be present in the same culture, but the Ags could be presented by two distinct populations of APC. When CD4+CD25+ T cells were cultured with anti-CD3 and IL-2, they expanded, remained anergic, and in the absence of restimulation via their TCR, suppressed Ag-specific responses of CD4+CD25- T cells from multiple TCR transgenics. Collectively, these data demonstrate that CD4+CD25+ T cells require activation via their TCR to become suppressive, but once activated, their suppressor effector function is completely nonspecific. The cell surface molecules involved in this T-T interaction remain to be characterized.
Similar articles
- Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S. Takahashi T, et al. Int Immunol. 1998 Dec;10(12):1969-80. doi: 10.1093/intimm/10.12.1969. Int Immunol. 1998. PMID: 9885918 - CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.
Thornton AM, Shevach EM. Thornton AM, et al. J Exp Med. 1998 Jul 20;188(2):287-96. doi: 10.1084/jem.188.2.287. J Exp Med. 1998. PMID: 9670041 Free PMC article. - Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells.
Piccirillo CA, Shevach EM. Piccirillo CA, et al. J Immunol. 2001 Aug 1;167(3):1137-40. doi: 10.4049/jimmunol.167.3.1137. J Immunol. 2001. PMID: 11466326 - Control of T-cell activation by CD4+ CD25+ suppressor T cells.
Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Shevach EM, et al. Immunol Rev. 2001 Aug;182:58-67. doi: 10.1034/j.1600-065x.2001.1820104.x. Immunol Rev. 2001. PMID: 11722623 Review. - TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression.
Chen W, Wahl SM. Chen W, et al. Cytokine Growth Factor Rev. 2003 Apr;14(2):85-9. doi: 10.1016/s1359-6101(03)00003-0. Cytokine Growth Factor Rev. 2003. PMID: 12651220 Review.
Cited by
- Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
Perrin S, Ladha S, Maragakis N, Rivner MH, Katz J, Genge A, Olney N, Lange D, Heitzman D, Bodkin C, Jawdat O, Goyal NA, Bornstein JD, Mak C, Appel SH, Paganoni S. Perrin S, et al. PLoS Med. 2024 Oct 31;21(10):e1004469. doi: 10.1371/journal.pmed.1004469. eCollection 2024 Oct. PLoS Med. 2024. PMID: 39480764 Free PMC article. Clinical Trial. - High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.
Cochrane RW, Robino RA, Granger B, Allen E, Vaena S, Romeo MJ, de Cubas AA, Berto S, Ferreira LMR. Cochrane RW, et al. bioRxiv [Preprint]. 2024 Apr 1:2024.03.31.587467. doi: 10.1101/2024.03.31.587467. bioRxiv. 2024. PMID: 38617240 Free PMC article. Preprint. - Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer.
Santry LA, van Vloten JP, AuYeung AWK, Mould RC, Yates JGE, McAusland TM, Petrik JJ, Major PP, Bridle BW, Wootton SK. Santry LA, et al. Front Microbiol. 2024 Jan 24;15:1325558. doi: 10.3389/fmicb.2024.1325558. eCollection 2024. Front Microbiol. 2024. PMID: 38328418 Free PMC article. - lncRNA XIST Interacts with Regulatory T Cells within the Tumor Microenvironment in Chronic Hepatitis B-Associated Hepatocellular Carcinoma.
Pehlivanoglu B, Aysal A, Agalar C, Egeli T, Ozbilgin M, Unek T, Unek IT, Oztop I, Aktas S, Sagol O. Pehlivanoglu B, et al. Turk Patoloji Derg. 2024;40(2):101-108. doi: 10.5146/tjpath.2023.13161. Turk Patoloji Derg. 2024. PMID: 38265097 Free PMC article. - Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.
Christofi P, Pantazi C, Psatha N, Sakellari I, Yannaki E, Papadopoulou A. Christofi P, et al. Cancers (Basel). 2023 Dec 17;15(24):5877. doi: 10.3390/cancers15245877. Cancers (Basel). 2023. PMID: 38136421 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous